PCSK9 Archives -

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce

Novartis bags elusive US approval for cholesterol drug inclisiran

https://pharmaphorum.com/news/novartis-bags-elusive-us-approval-for-cholesterol-drug-inclisiran/

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck &

Merck’s oral PCSK9 drug matches injectables in early trials

https://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/

Amgen searching for advantage over Sanofi rival.

Amgen’s cholesterol drug gets new monthly dose

https://pharmaphorum.com/news/amgens-cholesterol-drug-gets-new-monthly-dose/

Pfizer’s bococizumab cholesterol drug has met primary endpoint in two phase 3 trials, part of a series of

Pfizer cholesterol drug succeeds in two late stage trials

https://pharmaphorum.com/news/pfizer-cholesterol-drug-succeeds-two-late-stage-trials/

PCSK9